maspin suppresses the invasive phenotype of human breast carcinoma.
The recently discovered tumor suppressor gene maspin has been shown to inhibit tumor cell motility, invasion, and metastasis in breast cancer by our laboratories. Nonetheless, the exploitation of maspin as a potential diagnostic and/or therapeutic tool has remained limited due to the lack of knowledge concerning its molecular and biological mechanism(s) of action. The work reported here demonstrates that recombinant maspin (rMaspin) has the ability to induce higher cell surface levels of alpha5- and alpha3-containing integrins and reduced levels of alpha2-, alpha4-, alpha6-, alpha(v)-, and some beta1-containing integrins in the metastatic human breast carcinoma cell line MDA-MB-435 concomitant with its ability to inhibit the invasive process in vitro. Furthermore, treatment of MDA-MB-435 cells with rMaspin results in the selective adhesion of the cell to a fibronectin matrix and conversion from a fibroblastic to a more epithelial-like phenotype. In addition, the ability of rMaspin to inhibit the invasive process can be abrogated with a blocking antibody to the alpha5beta1 integrin, which diminishes the ability of the cells to invade through a fibronectin matrix-containing barrier in vitro. Taken together, these data address the hypothesis that rMaspin reduces the invasive phenotype of MDA-MB-435 cells by altering their integrin profile, particularly alpha5, which in turn converts these cells to a more benign epithelial phenotype, with less invasive ability. These data provide new insights into the biological significance of this tumor suppressor gene found in normal mammary epithelium and may form the basis of novel therapeutic strategies in the management of breast carcinoma.
Seftor
R E
RE
Department of Anatomy, The University of Iowa, College of Medicine, Iowa City 52242, USA.
Seftor
E A
EA
Sheng
S
S
Pemberton
P A
PA
Sager
R
R
Hendrix
M J
MJ
D019138:Antibodies, Blocking / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D002448:Cell Adhesion / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D016147:Genes, Tumor Suppressor; D006801:Humans; D016023:Integrins / Q000378:metabolism*; D009361:Neoplasm Invasiveness; D010641:Phenotype; D011506:Proteins / Q000494:pharmacology*; D017469:Receptors, Fibronectin / Q000276:immunology / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology; D015843:Serpins / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D019138:Antibodies, Blocking; D000970:Antineoplastic Agents; D016023:Integrins; D011506:Proteins; D017469:Receptors, Fibronectin; D011994:Recombinant Proteins; C085344:SERPIN-B5; D015843:Serpins